抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识

【摘要】 慢性荨麻疹是一种常见的免疫相关性皮肤病，具有反复发作、迁延不愈等特点，部分患者对常规抗组胺药物治疗效果不佳，生活质量受到严重影响。目前，国内外多项研究证实，一类以新型生物制剂为主的抗IgE疗法能够较为有效和安全地应用于慢性荨麻疹等疾病的治疗。为规范并促进临床医生对抗IgE疗法的应用和认识，基于国外指南及近年相关研究报道，中华医学会皮肤性病学分会荨麻疹研究中心组织有关专家制订本共识，以奥马珠单抗为代表，详细介绍抗IgE疗法治疗慢性荨麻疹的具体机制、应用方案和注意事项，为皮肤科医务工作者提供相关的理论依据和用药指导。

Consensus on management of chronic urticaria using anti-immunoglobulin E therapy （omalizumab）

【Abstract】 Chronic urticaria is a common immune-related skin disorder with a persistent and recurrent course. Some patients poorly respond to antihistamines, whose quality of life may be severely impaired. Recently, various Chinese and international studies have shown that the anti-immunoglobulin E （IgE） therapy, which is primarily based on new biologic agents, is effective and well-tolerated in the treatment of chronic urticaria and other diseases. In order to standardize and promote the application and understanding of anti-IgE therapy by clinicians, the Centre for Urticaria Research of Chinese Society of Dermatology organized relevant experts to develop this consensus on the basis of international guidelines and relevant research reports in recent years. By taking omalizumab as an example, this consensus elaborates on specific mechanisms and treatment schemes of anti-IgE therapy in the treatment of chronic urticaria, as well as considerations during its use, with a view to providing a relevant theoretical basis and medication guidance for dermatologists.